Mass. cancer drugmaker targets $125M from stock, options sale

07/12/2013 | American City Business Journals

Merrimack Pharmaceuticals could raise $125 million through stock offering and sale of convertible senior notes. The Cambridge, Mass.-based firm will mainly use the proceeds to support clinical studies, regulatory submissions and pre-approval commercial work for MM-398, its experimental drug for metastatic pancreatic cancer.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL